MEDPLUS Medplus Health Services Q1 FY26 results (Apr–Jun 2025) and concall
Medplus Health reported a mixed Q1 FY26, with consolidated revenue of ₹15,426 million and an operating EBITDA margin of 4.7%. The diagnostic segment showed strong growth and profitability. While store expansion continued with 101 net additions, overall growth was impacted by supply chain challenges and a strategic focus on private label, which, despite boosting margins, led to a temporary slowdown in topline growth. Management is addressing these issues and expects SSG recovery in the coming quarters.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 156 | 177 | 202 | 184 |
| EBITDA | 17 | 19 | 24 | 24 |
| Net profit | 8 | 9 | 14 | 14 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
